Skip to content

IND (Investigational New Drug application)

Last reviewed

An Investigational New Drug application (IND) is the submission a sponsor makes to the US FDA before starting clinical trials of a new drug or biologic in the United States. Trials may begin 30 days after the FDA receives the IND, unless the agency places the study on clinical hold.

Key facts

Regulation21 CFR Part 312
Main contentsAnimal pharmacology and toxicology data, manufacturing information, and clinical protocols and investigator information
Ongoing obligationAn annual report; the FDA accepts a DSUR in its place
Broadly comparable in the EUClinical Trial Application (CTA)

IND and NDA

The IND allows clinical investigation to start. The New Drug Application (NDA), or the Biologics License Application (BLA) for biologics, comes at the end of development and asks for approval to market the product.

Sources

Read more